Navigation Links
NORD Sponsors Rare Disease Summit
Date:5/14/2009

WASHINGTON, May 14 /PRNewswire-USNewswire/ -- A shortage of new pharmaceutical products in the pipeline combined with new scientific tools has created a climate of opportunity for the rare disease community, a senior Food and Drug Administration (FDA) official said today at a conference hosted by the National Organization for Rare Disorders (NORD).

The blockbuster model is no longer viable, said Janet Woodcock, MD, director of the Center for Drug Evaluation and Research at FDA. As a result, she said, companies are more willing to consider new options, including more products for rare diseases.

Former National Human Genome Research Institute Director Francis Collins, MD, PhD, agreed, adding that it's time to de-risk orphan drug development, making it a more viable business model for companies.

Collins and Woodcock were among several speakers at a Partners in Progress Summit hosted by NORD in Washington, DC. NORD represents the nearly 30 million Americans who have rare diseases, or ones affecting fewer than 200,000 people.

Peter L. Saltonstall, NORD's president and CEO, noted that most rare diseases have no FDA-approved treatment and many patients are denied insurance for unapproved treatments. NORD sponsored the summit, he said, to develop a policy agenda for action to spur development of new therapies and ensure that patients have access to them.

Former FDA Commissioner David Kessler, MD, moderated the event. Speakers included thought leaders in government and industry working with rare diseases and orphan products. A theme articulated by several speakers was that now is the time for rare disease patients and researchers to press their case.

The healthcare system we know today is going to be completely transformed over the next 12 months, said Tommy Thompson, former governor of Wisconsin and former Secretary of Health and Human Services. Now is the time for action.

NORD Board of Directors Vice Chairman Frank Sasinowski announced the formation of a Rare Disease Congressional Caucus to seek creative solutions to problems faced by patients and to serve as a forum for discussion of issues related to access, research, and increased innovation.

The Caucus will also seek to increase funding for two government agencies the National Institutes of Health Office of Rare Diseases Research and the FDA Office of Orphan Products Development. In addition, it will address regulatory issues facing the pharmaceutical, biotechnology, and medical device industries, Sasinowski said.

Social Security Commissioner Michael Astrue described efforts to expedite the process of applying for Social Security disability assistance for people with severely disabling rare diseases. Under Commissioner Astrue, the Social Security Administration last fall launched a new Compassionate Allowances initiative to reduce problems encountered by people with certain severe diseases when they apply for assistance.

Presentations from the Partners in Progress Summit will be posted soon on the NORD website at www.rarediseases.org.


'/>"/>
SOURCE National Organization for Rare Disorders (NORD)
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Duane Reade Announces Premier-Level Sponsorship of AIDS Walk New York
2. HealthCentral.com Collaborates With BreastCancer.org, Providing Quality Awareness Sponsorships to #1 Breast Cancer Resource Online
3. Co-Sponsorship of Pulmonary Fibrosis Research Enhancement Act 2009 Increases to 27 Members
4. Celebrate the Beauty of Motherhood - American Laser Centers Sponsors RoleMommy.com Mothers Day Spa Retreat & Style Lounge
5. Cosmetic Bootcamp Announces Sold Out Sponsorship for Upcoming Meeting
6. Turtle Island Oxygen Trust Sponsors Free Hyperbaric Treatments
7. Cardinal Rigali Praises House Re-Introduction of Pregnant Women Support Act, Urges Co-Sponsorship
8. Prime Sponsors at 2009 American Heart Walk
9. Paying it Forward: Washington, DC LASIK Vision Care Practice Sponsors New Contest to Reward Good Deeds
10. American Laser Centers Sponsors SELF Magazines Workout in the Park
11. Elekta Sponsors All Are Our Heroes to Raise Cancer Awareness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... ... committed to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne ... (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne announced today. , ...
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now accepting ... Invisalign® in Lutz, FL. With the help of this highly-effective, yet convenient system, ... potential complications, more discretion and less pain. , Drs. Sarah Jockin, Nicole Morganti, ...
(Date:4/25/2017)... ... April 25, 2017 , ... Buyers and sellers in the thriving ... and head shops –can’t help but be heartened by the industry’s current surge. But ... aptly described as “skunk smell.” At last they can simply, safely and effectively ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, at this ... joint health in horses at the immunologic level. , The scientifically-developed Flexadin UCII ...
(Date:4/24/2017)... ... 24, 2017 , ... The Santana Telehealth Project was honored with the 2017 ... American Telemedicine Association’s annual conference, on April 23 in Orlando, FL. , “I am ... the lives of the poor and underserved in other parts of the world,” said ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology: